Discover
ORKA
Oruka Therapeutics, Inc.
94.32
1 x 85.42
1 x 97.70
bid
ask
+
2.61
2.85%
3 @ 04:00 PM
94.50 +0.18 (0.19%)
| Ytd | 211.18% | |
| 1y | 570.84% |
92.31
day range
96.00
12.84
52 week range
97.78
| Open | 93.14 | Prev Close | 91.71 | Low | 92.31 | High | 96.00 | Mkt Cap | 3.53B |
| Vol | 585.51K | Avg Vol | 1.79M | EPS | -1.94 | P/E | -48.62 | Forward P/E | -34.83 |
| Beta | -0.35 | Short Ratio | 5.59 | Inst. Own | 92.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 73.16 | 200-d Avg | 46.21 | 1yr Est | 144.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-10 | 2026-06 | -0.49 | N/A | N/A | N/A |
| 2026-05-13 | 2026-03 | -0.55 | -0.48 | 0.07 | 12.24% |
| 2026-03-12 | 2025-12 | -0.61 | -0.45 | 0.16 | 26.23% |
| 2025-11-12 | 2025-09 | -0.56 | -0.55 | 0.01 | 1.79% |
| 2025-08-11 | 2025-06 | -0.48 | -0.46 | 0.02 | 4.17% |
| 2025-05-14 | 2025-03 | -0.57 | -0.4 | 0.17 | 29.82% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-13 | BTIG | Upgrade | Buy | Buy |
| 2026-07-01 | UBS | Upgrade | Buy | Buy |
| 2026-06-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-14 | BTIG | Upgrade | Buy | Buy |
| 2026-04-29 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-21 | AGARWAL ARJUN | Officer | 15.31K | Sale |
| 2026-06-11 | DAMBKOWSKI CARL | Director | 38.74K | Sale |
| 2026-06-30 | FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2026-06-14 | GONCALVES JOANA | Officer | 32.72K | Conversion of Exercise of derivative security |
| 2024-08-15 | JANUS HENDERSON GROUP PLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-06-14 | KLEIN LAWRENCE OTTO | Chief Executive Officer | 925.58K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR Inc | 7.43M | 0.00 | 12.32% |
| 2026-03-30 | VR Adviser, LLC | 4.15M | 0.00 | 6.88% |
| 2026-03-30 | Fairmount Funds Management LLC | 3.71M | 0.00 | 6.14% |
| 2026-03-30 | BlackRock Inc | 3.53M | 0.00 | 5.85% |
| 2026-03-30 | Viking Global Investors LP | 2.67M | 0.00 | 4.42% |
| 2025-12-30 | Vanguard Group Inc | 2.45M | 0.00 | 4.07% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 1.73M | 0.00 | 2.86% |
| 2026-05-30 | Fidelity Growth Compy Commingled Pl S | 1.64M | 0.00 | 2.72% |
| 2026-06-29 | State Street® SPDR® S&P® Biotech ETF | 1.55M | 0.00 | 2.57% |
| 2026-06-29 | American Funds New Economy A | 1.32M | 0.00 | 2.19% |
| 2026-06-29 | iShares Russell 2000 ETF | 1.32M | 0.00 | 2.19% |
| 2026-05-30 | Fidelity Growth Company Fund | 1.22M | 0.00 | 2.02% |
Dividend
| Dividend | Date |
|---|---|
| 1.613 | 2024-08-29 |